Bromelain topical - MediWound

Drug Profile

Bromelain topical - MediWound

Alternative Names: Debrase; Debrase Gel Dressing; NexoBrid; NexoBridN

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediWound
  • Developer MediWound; Teva Pharmaceutical Industries; Tuteur
  • Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Burns

Most Recent Events

  • 16 Oct 2017 Bromelain topical licensed to Holy Stone Healthcare in Taiwan
  • 03 Aug 2017 MediWound submits protocol for the phase III Children Innovative Debridement Study with the US FDA in USA for Burns (In adolescents, In children, In infants)
  • 30 Jun 2016 Launched for Burns in Argentina (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top